deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04886258

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis

Sponsor: Novartis Pharmaceuticals

Conditions Symptomatic Knee Osteoarthritis
Interventions DFV890 Placebo
Updated 32 times since 2021 Last updated: Jan 12, 2026 Started: Sep 20, 2021 Primary completion: Dec 14, 2024 Completion: Dec 23, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04886258, this PHASE2 trial focuses on Symptomatic Knee Osteoarthritis and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 32 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~May 2023 · 4 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jun 2024 · 3 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Jun 2025 · 3 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

32 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE2

  3. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE2

  4. Mar 2025 — Jun 2025 [monthly]

    Completed PHASE2

  5. Feb 2025 — Mar 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 27 earlier versions

  1. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  6. Mar 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  7. Jan 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  8. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  9. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  10. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  11. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  12. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  13. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  14. Jan 2023 — May 2023 [monthly]

    Recruiting PHASE2

  15. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  16. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  17. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  18. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  19. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  20. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  21. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  22. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  23. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  24. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  25. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  26. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE2

  27. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Bad Doberan, Germany , Barcelona, Spain , Berlin, Germany , Brno, Czechia , Bucharest, Romania , Budapest, Hungary , CABA, Argentina , Chicago, United States , Cluj-Napoca, Romania and 20 more locations